Treasury Board of Canada Secretariat
www.tbs-sct.gc.ca
Common menu bar links
Breadcrumb Trail
ARCHIVED - Patented Medicine Prices Review Board - Report
This page has been archived.
Archived Content
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
Section III — Supplementary Information
Financial Highlights
The Patented Medicine Prices Review Board (PMPRB) entered the 2009-2010 year with stable funding commensurate with its projected workload pressures.
Primary attention was given to critical activities such as the completion of the Guidelines review and the conduct of more complex and numerous price reviews, investigations and hearings.
The retrofit of PMPRB facilities to accommodate new FTEs was completed.
Effort was also dedicated to re-programming the mission-critical database to accommodate price test changes while preparing to re-develop the database using a newer technology.
The financial highlights presented within this Department Performance Report are intended to serve as a general overview of the PMPRB’s financial position and operations. The Board’s financial statements can be found on the Board’s Web site at http://www.pmprb-cepmb.gc.ca/CMFiles/2009-10_Financial_Statement_English_signed.pdf.
| Condensed Statement of Financial Position At End of Year (March 31, 2010) |
% Change | 2008–09 | 2009–10 |
|---|---|---|---|
| Assets | |||
| Total Assets | 298.0% | $854.7 | $3,402.0 |
| Liabilities | |||
| Total Liabilities | 123.4% | $2,068.9 | $4,622.3 |
| Equity | |||
| Total Equity | (0.5%) | ($1,214.2) | ($1,220.2) |
| Total | 298.0% | $854.7 | $3,402.0 |
| Condensed Statement of Operations At End of Year (March 31, 2010) |
% Change | 2008–09 | 2009–10 |
|---|---|---|---|
| Expenses | |||
| Total Expenses | 10.2% | $9,257.7 | $10,204.3 |
| Revenues | |||
| Total Revenues | (2.2%) | $24,760.0 | $24,204.6 |
| Net Cost of Operations | (9.7%) | ($15,502.3) | ($14,000.3) |
Supplementary Information Tables
All electronic supplementary information tables listed in the 2009-2010 Departmental Performance Report can be found on the Treasury Board of Canada Secretariat’s web site at http://www.tbs-sct.gc.ca/dpr-rmr/st-ts-eng.asp
Sources of Non-Respendable Revenue
Green Procurement
Other Items of Interest
PMPRB Annual Report 2009 (http://www.pmprb-cepmb.gc.ca/English/View.asp?x=91&mp=68)
Quarterly NEWSletter (http://www.pmprb-cepmb.gc.ca/English/View.asp?x=287&mp=68)
Patentee’s Guide to Reporting (http://www.pmprb-cepmb.gc.ca/english/view.asp?x=146)
Compendium of Guidelines, Policies and Procedures (March 2008)
(http://www.pmprb-cepmb.gc.ca/english/view.asp?x=1034)
Compendium of Policies, Guidelines and Procedures, June 2009 (implementation January 1, 2010) (http://www.pmprb-cepmb.gc.ca/english/View.asp?x=1206&mp=808)
Patent Act (http://laws.justice.gc.ca/en/P-4/index.html)
Patented Medicines Regulations (http://laws.justice.gc.ca/en/P-4/SOR-94-688/index.html)
1Commencing in the 2009-2010 Estimates cycle, the resources for Program Activity: Internal Services is displayed separately from other program activities; they are no longer distributed among the remaining program activities, as was the case in previous Main Estimates. This has affected the comparability of spending and FTE information by Program Activity between fiscal years.
2 Total Authorities and Actual Spending have been adjusted to reflect the Employee Benefit Plan (EBP) within the Internal Services Program Activity, as per the Public Accounts; and prejudgment and postjudgment interest in the amount of $169,500, as per the Order of the Federal Court in the matter of Teva Neuroscience G.P.-S.E.N.C. v. Attorney General of Canada 2009FC1206.
3The PMPRB has only one Strategic Outcome (SO), and all priorities are linked to that SO.
4Actual Spending has been adjusted to reflect the EBP within the Internal Services Program Activity, as per the Public Accounts; and prejudgment and postjudgment interest in the amount of $169,500, as per the Order of the Federal Court in the matter of Teva Neuroscience G.P.-S.E.N.C. v. Attorney General of Canada 2009FC1206.
5Total Authorities and Actual Spending have been adjusted to reflect the EBP within the Internal Services Program Activity, as per the Public Accounts; and prejudgment and postjudgment interest in the amount of $169,500, as per the Order of the Federal Court in the matter of Teva Neuroscience G.P.-S.E.N.C. v. Attorney General of Canada 2009FC1206.
6A Voluntary Compliance Undertaking (VCU) is a written undertaking by a patentee to adjust the price of a patented drug product to conform to the Guidelines and to offset excess revenues.
7Total Authorities and Actual Spending have been adjusted to reflect the EBP within the Internal Services Program Activity, as per the Public Accounts.
8Total Authorities and Actual Spending have been adjusted to reflect the EBP within the Internal Services Program Activity, as per the Public Accounts.
